| Literature DB >> 35548893 |
Tamer Z Attia1, John M Boushra2, Ahmed F Abdel Hakiem3, Adel S Lashien2, Deena A M Noureldeen1.
Abstract
Following the sudden widespread of the novel coronavirus (COVID-19) which first appeared in Wuhan city. Remdesivir (REM) was the first medicine licensed by the US Food and Drug Administration (FDA) for COVID-19 infected hospitalized patients. Hence, there was an urgent demand for the optimization of efficient selective and sensitive methods to be developed for the determination of REM in pharmaceuticals as well as biological samples. A sensitive and simple green spectrofluorimetric method has been developed to determine REM in pharmaceutical formulation, in addition to, spiked human plasma. The technique involves measuring the native fluorescence of REM in distilled water at 410 nm followed by excitation at 241 nm, giving a linear relationship over the range 50.00-500.00 ng/mL, and then improving the sensitivity of REM through micellar formation using 2.00% w/v sodium dodecyl sulfate (SDS). A linear relationship has been obtained over the range 10.00-350.00 ng/mL having detection and quantitation limits of 2.34 and 7.10 ng/mL, respectively. Different analytical parameters have been carefully studied. A validation study has been conducted successfully in accordance with the FDA and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. The developed methods' greenness was assessed utilizing a greenness profile and analytical eco-scale standards. Both methods were discovered to be environmentally friendly and could be successfully used for the determination of the studied drugs in pharmaceutical formulation and human plasma with good accuracy and high precision. As a result, the developed spectrofluorimetric methods could be ideally suited for determination of REM in quality control and medicinal laboratories.Entities:
Keywords: COVID-19; human plasma; remdesivir; spectrofluorimetry
Mesh:
Substances:
Year: 2022 PMID: 35548893 PMCID: PMC9348023 DOI: 10.1002/bio.4274
Source DB: PubMed Journal: Luminescence ISSN: 1522-7235 Impact factor: 2.613
FIGURE 1Chemical structure of remdesivir (REM)
FIGURE 2The fluorescence spectra of 200.00 ng/mL remdesivir (REM), where (A) and (B) are the excitation and emission spectra of its aqueous solution, respectively, (C) and (D) are the excitation and emission spectra of REM in 2.00% w/v sodium dodecyl sulfate (SDS) aqueous solution, respectively, and (E) and (F) are blank excitation and emission
FIGURE 3The effect of different surfactants (2.50 mL of 2.00% w/v or v/v solution of each) on the relative fluorescence intensity of remdesivir (REM) (300.00 ng/mL)
FIGURE 4The effect of sodium dodecyl sulfate (SDS) volume (2.00%w/v) on the relative fluorescence intensity of remdesivir (REM) (300.00 ng/mL)
FIGURE 5The effect of diluting solvent on the relative fluorescence intensity of remdesivir (REM) (300.00 ng/mL)
FIGURE 6The effect of diluting solvent on the relative fluorescence intensity of remdesivir (REM) [300.00 ng/mL in 2.00% w/v solution of sodium dodecyl sulfate (SDS)]
Analytical parameters for determination of remdesivir (REM) by the proposed spectrofluorimetric methods
| Parameters | Method 1 | Method 2 |
|---|---|---|
| Linearity (ng/mL) | 50.00–500.00 | 10.00–350.00 |
| Correlation coefficient ( | 0.9998 | 0.9999 |
| Determination coefficient ( | 0.9997 | 0.9999 |
| Slope ( | 0.5906 | 0.8159 |
| Intercept ( | 6.6705 | 2.7847 |
| Standard deviation of slope | 0.004 | 0.003 |
| Standard deviation of intercept | 1.31 | 0.58 |
| LOD (limit of detection) (ng/mL) | 7.31 | 2.34 |
| LOQ (limit of quantitation) (ng/mL) | 22.15 | 7.10 |
Evaluation of the accuracy of the proposed methods in determining remdesivir (REM)
| Parameters | Method 1 | Method 2 | ||||
|---|---|---|---|---|---|---|
| Taken (ng/mL) | Found | Recovery (%) | Taken (ng/mL) | Found | Recovery (%) | |
| 1 | 100.00 | 99.42 | 99.41 | 40 | 40.83 | 102.10 |
| 2 | 200.00 | 201.81 | 100.90 | 70 | 71.69 | 102.41 |
| 3 | 250.00 | 252.44 | 100.97 | 120 | 120.72 | 100.60 |
| 4 | 300.00 | 301.64 | 100.54 | 200 | 200.14 | 100.10 |
| 5 | 500.00 | 493.82 | 98.76 | 300 | 299.45 | 99.81 |
| Mean | 100.12 | 100.99 | ||||
| Standard deviation | 0.98 | 1.18 | ||||
| Percent relative standard deviation | 0.98 | 1.20 | ||||
Average of three determinations.
Precision study for the developed methods
| Parameters | Method 1 | Method 2 | |||||
|---|---|---|---|---|---|---|---|
| 100.00 ng/mL | 200.00 ng/mL | 300.00 ng/mL | 40.00 ng/mL | 120.00 ng/mL | 200.00 ng/mL | ||
| Intra‐day | 1 | 98.70 | 101.15 | 101.64 | 101.77 | 100.67 | 99.73 |
| 2 | 99.71 | 100.23 | 99.44 | 102.51 | 100.27 | 100.23 | |
| 3 | 99.83 | 101.32 | 100.55 | 101.96 | 100.86 | 100.24 | |
| Mean | 99.41 | 100.90 | 100.54 | 102.10 | 100.60 | 100.10 | |
| SD | 0.62 | 0.58 | 1.10 | 0.38 | 0.29 | 0.29 | |
| %RSD | 0.63 | 0.58 | 1.10 | 0.37 | 0.29 | 0.29 | |
| Inter‐day | 1 | 99.83 | 100.23 | 100.55 | 101.77 | 100.67 | 99.73 |
| 2 | 101.90 | 99.75 | 99.77 | 100.97 | 100.10 | 99.10 | |
| 3 | 99.90 | 97.97 | 97.99 | 101.58 | 99.86 | 98.85 | |
| Mean | 100.52 | 98.86 | 99.44 | 101.44 | 100.20 | 99.22 | |
| SD | 1.16 | 1.27 | 1.31 | 0.42 | 0.42 | 0.45 | |
| %RSD | 1.15 | 1.27 | 1.32 | 0.41 | 0.42 | 0.46 | |
SD, standard deviation; %RSD, percent relative standard deviation.
Evaluation of remdesivir (REM) in its pharmaceutical formulation by the developed spectrofluorimetric methods with application of standard addition technique, and statistical comparison of the obtained results using the reported high‐performance liquid chromatography (HPLC) method[ ]
| Pharmaceutical formulation | Methods | Found | Standard addition technique | Reported method |
|
| |
|---|---|---|---|---|---|---|---|
| Added (ng/mL) | Recovery (%) | ||||||
| Remdesivir‐Rameda® for intravenous injection (100 ng/mL) | Method 1 | 101.10 ± 0.60 | 50 | 99.41 | 100.68 ± 0.61 | 1.077 | 1.039 |
| 100 | 99.91 | ||||||
| 200 | 98.48 | ||||||
| Mean (% ± standard deviation) | 99.27 ± 0.72 | ||||||
| Method 2 | 100.27 ± 0.90 | 50 | 99.22 | 0.831 | 2.139 | ||
| 100 | 99.84 | ||||||
| 200 | 99.01 | ||||||
| Mean (% ± standard deviation) | 99.36 ± 0.42 | ||||||
Mean of five determinations.
Mean of three determinations.
The tabulated values of t‐test and F‐test at 0.05% are 2.306 and 6.388, respectively.
Application of the proposed methods to spiked human plasma samples
| Parameters | Taken (ng/mL) | Method 1 | Method 2 | ||
|---|---|---|---|---|---|
| Found | Recovery (%) | Found | Recovery (%) | ||
| 1 | 50.00 | 49.87 | 99.74 | 49.18 | 98.37 |
| 2 | 100.00 | 99.27 | 99.27 | 98.87 | 98.87 |
| 3 | 200.00 | 197.25 | 98.62 | 198.22 | 99.11 |
| 4 | 300.00 | 295.73 | 98.57 | 295.42 | 98.47 |
| 5 | 350.00 | 341.78 | 97.65 | 347.17 | 99.19 |
| Mean | 98.77 | 98.80 | |||
| Standard deviation | 0.79 | 0.37 | |||
| Percent relative standard deviation | 0.80 | 0.37 | |||
Average of three determinations.
Greenness assessment of the proposed methods by analytical eco‐scale and NEMI
| Eco‐scale | NEMI pictogram | ||||
|---|---|---|---|---|---|
| Parameters | Method 1 | Method 2 | Method 1 | Method 2 | |
| Penalty points | Penalty points | ||||
| Reagents | Water | 0 | 0 |
|
|
| SDS | — | 0 | |||
| Instrument | 1 | 1 | |||
| Occupational hazard | 0 | 0 | |||
| Waste | 6 | 6 | |||
| Total penalty points | 7 | 7 | |||
| Analytical eco‐scale score | 93 | 93 | |||
NEMI, National Environmental Method Index; SDS, sodium dodecyl sulfate; PBT, non‐persistent, bio‐accumulative and toxic solvents.